Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

INDIANAPOLIS, Sept. 24, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) is voluntarily recalling lot D239382D, Expiration April 2022, of Glucagon Emergency Kit for Low Blood Sugar (Glucagon for Injection, 1 mg per vial; Diluent for Glucagon, 1 mL syringe), to the consumer/user level.

Eli Lilly and Company Issues Voluntary Nationwide Recall of One Lot of GLUCAGON® Emergency Kit Due to Loss of Potency

Elli Lilly (LLY) is set to supply 220,000 doses of its COVID-19 antibody cocktail to European Union member nations, following approval.

Lilly (LLY) to Supply COVID Cocktail Drug to EU Countries

INDIANAPOLIS, Sept. 21, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the pricing terms of its previously announced cash tender offer for specified series of its outstanding debt securities.

Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities

INDIANAPOLIS, Sept. 21, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a Joint Procurement Agreement with the European Commission (EC) to supply up to 220,000 doses of bamlanivimab and etesevimab for the treatment of confirmed COVID-19 in patients aged 12 years and older who do not require supplemental oxygen for COVID-19 and who are at increased risk of progressing to severe COVID-19.

Lilly announces procurement agreement with European Commission to supply bamlanivimab and etesevimab together for the treatment of confirmed COVID-19

INDIANAPOLIS, Sept. 21, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the early tender results of its previously announced cash tender offer for specified series of its outstanding debt securities.

Lilly Announces the Early Tender Results of Its Pending Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities and Removal of the Note Caps for Its 3.950% Notes due 2049 and Its 4.150% Notes due 205

Bristol-Myers

Johnson & Johnson

Merck

Pfizer

Drug stocks are in a tailspin, and you need to look no farther than Washington for the primary reason. A White House plan to cut the price of medications has led to a more than 10% drop in the Dow Jones U.S. Pharmaceuticals Index over the past month as investors bailed on Big Pharma, concerned that any price controls would eat into sales and profits.

Big Pharma Stocks Hit Hard by Drug Price Proposals

FDA revises Lilly's (LLY) EUA for COVID-19 antibody cocktail, bamlanivimab and etesevimab, for post-exposure prophylaxis for COVID-19.

Lilly (LLY) Gets FDA Nod for Expanded Use of COVID Cocktail

Drug maker Eli Lilly And Co   (NYSE:LLY) is making headlines this morning, after the U.S. Food and Drug Administration (FDA) revised an emergency use authorization for the antibody cocktail the company has developed with AbCellera (ABCL) to treat Covid-19 cases.

FDA Revision Puts Eli Lilly Stock in Spotlight

AbCellera Biologics

The FDA has expanded the Emergency Use Authorization (EUA) for bamlanivimab 700 mg and etesevimab 1400 mg administered together to include post-exposure prophylaxis in certain individuals to prevent SARS-CoV-2 infection.  Bamlanivimab emerged from the collaboration between Eli Lilly And Co (NYSE: LLY) and AbCellera Biologics Inc (NASDAQ: ABCL).

AbCellera Stock Is Moving Higher After Expanded Use Nod For Lilly-Partnered COVID-19 Antibody

INDIANAPOLIS, Sept. 16, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab 700 mg and etesevimab 1400 mg administered together to include post-exposure prophylaxis (PEP) in certain individuals for the prevention of SARS-CoV-2 infection, Eli Lilly and Company (NYSE: LLY) announced today.

Emergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19

Regeneron Pharmaceuticals

Regeneron (REGN) is set to supply an additional 1.4 million doses of its antibody cocktail for COVID-19, REGEN-COV while Lilly (LLY) will supply 388,000 doses of its COVID-19 antibody medicine, etesevimab to the U.S. government.

Regeneron, Lilly Get New COVID Drug Deals From Government

The U.S. government has announced to purchase additional doses of Eli Lilly And Co's (NYSE: LLY) for its neutralizing antibody therapies for COVID-19. Related Link: Distribution Resumes Of Eli Lilly COVID-19 Antibody Therapies.

After Regeneron, US Government Orders Additional COVID-19 Therapy From Eli Lilly

Eli Lilly & Co. LLY, -2.05% announced Wednesday to sell 388,000 doses of etesevimab, which has been authorized for emergency use as a COVID-19 treatment for $330 million. As part of the deal, about 200,000 doses of etesevimab, which complements doses of bamlanivimab previously purchased by the U.S. government, are expected to ship in the third quarter of 2021, with the remaining doses to be shipped in the fourth quarter.

Eli Lilly to supply the U.S. government with doses of COVID-19 treatment etesevimab for $330 million

INDIANAPOLIS, Sept. 15, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced an additional purchase by the U.S. government for its neutralizing antibody therapies authorized for emergency use as a treatment for COVID-19.

Lilly to supply 388,000 doses of etesevimab to U.S. government for treatment of COVID-19

Eli Lilly and Company (LLY) Management Presents at Morgan Stanley 19th Annual Global Healthcare Conference (Transcript)

INDIANAPOLIS, Sept. 13, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021.

Lilly to Participate in the 2021 Cantor Virtual Global Healthcare Conference

INDIANAPOLIS, Sept. 13, 2021 /PRNewswire/ -- New data from various studies of Eli Lilly and Company's (NYSE: LLY) Verzenio® (abemaciclib), Retevmo® (selpercatinib) and CYRAMZA® (ramucirumab) will be presented at the European Society for Medical Oncology (ESMO) Congress 2021, to be held virtually September 16-21.

Lilly to Present New Data from Oncology Portfolio at ESMO Congress

Why Eli Lilly's COVID Antibody Therapy Is Making a Comeback

The FDA bestows a Breakthrough Therapy status on Lilly's (LLY) Jardiance for heart failure with preserved ejection fraction (HFpEF).

Lilly's (LLY) Jardiance Gets Breakthrough Therapy Tag for HFpEF

Eli Lilly and Company (LLY) Management Presents at Citi's 16th Annual BioPharma Virtual Conference (Transcript)

INDIANAPOLIS, Sept. 9, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the pricing of its first sustainability bond to advance its global environmental, social and governance (ESG) strategy to increase access to medicines, improve lives and communities, empower a diverse workforce, minimize environmental impact and operate ethically and responsibly.

Lilly Prices First Sustainability Bond to Advance Global ESG Strategy

INGELHEIM, Germany & INDIANAPOLIS--(BUSINESS WIRE)--Empagliflozin receives Breakthrough Therapy Designation in U.S. for heart failure with preserved ejection fraction (HFpEF)

Empagliflozin receives Breakthrough Therapy Designation in U.S. for heart failure with preserved ejection fraction (HFpEF)

RIDGEFIELD, Conn. and INDIANAPOLIS, Sept.

FDA grants Jardiance® Breakthrough Therapy designation for heart failure with preserved ejection fraction

Eli Lilly And Co (NYSE: LLY) is doubling down on RNA research as it pens another pact with a quiet RNA editing player focused on neuroscience, ProQR Therapeutics N.V. (NASDAQ: PRQR).

Eli Lilly Inks Another RNA Collab, This Time With ProQR

INDIANAPOLIS, Sept. 7, 2021 /PRNewswire/ -- Lilly Diabetes will commit nearly $1 million over the next three years in a joint effort with The Leona M.

News for Eli Lilly Stock (LLY)